IRCT201509031031N17
Completed
Phase 1
A phase I clinical trial on the use of autologous bone marrow mesenchymal stem cells for treatment of chronic kidney disease
Department of Regenerative Biomedicine, Cell Science Research Center, Royan Institute for Stem Cell0 sites10 target enrollmentTBD
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Chronic Kidney Disease.
- Sponsor
- Department of Regenerative Biomedicine, Cell Science Research Center, Royan Institute for Stem Cell
- Enrollment
- 10
- Status
- Completed
- Last Updated
- 8 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Inclusion Criteria: CKD confirmed with serum and urine analysis and GFR 25\-60 mL/min; Male and Female; CKD (more than 3 months with increased and irreversible creatinine) symptoms; Patients with controlled hypertension; Patient's age between 40\-60 years; Ability to understand and willingness to sign consent form
Exclusion Criteria
- •Pregnant or lactating; Vascular disease; Diabetes mellitus; Other systemic disease such as malignancy, autoimmune disease, hematologic disease, liver disease and …; Chronic rejection in transplantation; Life expectancy less than 2 years; Allergy to any ingredients used in cell culture; Congenital or acquired obstructive chronic renal failure; Unable to attend at follow up visits
Outcomes
Primary Outcomes
Not specified
Similar Trials
Terminated
Phase 1
A clinical trial of adoptive T-cell immunotherapy for patients with Epstein-Barr virus-associated nasopharyngeal carcinoma.Metastatic nasopharyngeal carcinomaCancer - Head and neckACTRN12613000866707QIMR Berghofer Medical Research Institute18
Recruiting
Phase 1
A phase I/II clinical study of expanded autologous NK cell combined with rituximab-based chemotherapy in patients with CD20 positive B-cell lymphomarelapsed/refractory CD20 positive B-cell lymphomaJPRN-UMIN000014072Department of Hematology, Tokyo Women's Medical University10
Completed
Phase 1
This study is assessing the feasibility of generating expanded T cells for the treatment of cytomegalovirus (CMV) reactivation and disease, and the subsequent evaluation of safety.CytomegalovirusInfection - Other infectious diseasesACTRN12613000981729QIMR Berghofer Medical Research Institute.30
Completed
Not Applicable
Does autologous platelet rich plasma help in improvement of vision in patients of retinitis pigmentosa?Health Condition 1: H355- Hereditary retinal dystrophyCTRI/2021/10/037501GSVM Medical College39
Completed
Not Applicable
Investigator-initiated clinical trial: Autologous peripheral blood-derived CD34+ cells transplantation for bone and vascular regeneration using with MB-001 and IK-02 in patients with Fracture non-union.Fracture non-unionJPRN-UMIN000022814Foundation for Biomedical Research and Innovation at Kobe15